Loading...
ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment
Clamp, Andrew R James, E. C. McNeish, I. Dean, A. Kim, J. W. O'Donnell, D. M. Hook, J. Gallardo-Rincon, D. Coyle, C. Blagden, S.
Clamp, Andrew R
James, E. C.
McNeish, I.
Dean, A.
Kim, J. W.
O'Donnell, D. M.
Hook, J.
Gallardo-Rincon, D.
Coyle, C.
Blagden, S.
Citations
Altmetric:
Abstract
Background: ICON8 investigated the safety and efficacy of weekly dose dense
chemotherapy (q1w) in patients with epithelial ovarian cancer (EOC) compared to
standard three weekly chemotherapy (q3w). ICON8 had co-primary outcomes of
progression free (PFS) and overall survival (OS). Mature OS and updated PFS results
are reported here.
Methods: Eligible women with FIGO stage IcG3-IV EOC were randomised 1:1:1 to arm 1
standard chemotherapy (q3w carboplatin AUC5/6 + q3w paclitaxel 175mg/m2); arm 2
weekly paclitaxel (q3w carboplatin AUC5/6 + q1w paclitaxel 80mg/m2); arm 3 weekly
carboplatin-paclitaxel (q1w carboplatin AUC2 + q1w paclitaxel 80mg/m2). Patients
received immediate primary surgery (IPS) prior to entering ICON8 or neo-adjuvant
chemotherapy with planned delayed primary surgery (DPS) during chemotherapy.
Analyses are performed on an intention to treat basis, comparing arms 2v1 and 3v1.
Results: From Jun 2011 - Nov 2014, 1566 patients were randomised, 522, 523, 521 in
arms 1, 2, 3 respectively. Baseline characteristics were well-balanced e median age
62 years; serous histology 72%; stage Ic-II 19%, IIIa-IIIb 10%, IIIc-IV 72%. 48% patients
had IPS, 50% planned DPS and 2% inoperable. At 1st Oct 2019, 923 deaths had been
reported, arm 1 319 (61%); arm 2 300 (57%); arm 3 304 (58%). No significant
improvement in OS was observed in either comparison: arm 2v1 log rank p¼0.14,
hazard ratio (HR) ¼ 0.88 (97.5% confidence interval (CI) 0.74, 1.06); arm 3v1 log rank
p¼0.27, HR ¼ 0.91 (97.5% CI 0.76, 1.09). Median OS was 47.4, 54.1 and 53.4 months
in arms 1, 2, 3 respectively. No heterogeneity in treatment effect was noted on
subgroup analysis by surgical approach (IPS vs DPS). Updated PFS was also analysed.
As in the primary analysis, no significant difference in PFS was observed with either
weekly treatment (log-rank arm 2v1 p¼0.37, arm 3v1 p¼0.48; restricted mean PFS
time 25, 25.5, 25.9 months in arms 1, 2, 3 respectively).
Conclusions: The final analysis for ICON8 confirms that, although weekly dose-dense
chemotherapy is a safe alternative to q3w chemotherapy and can be delivered successfully
in first-line EOC treatment, it does not significantly improve PFS or OS.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 146.65 KB
Keywords
Type
Meetings and Proceedings
Citation
Clamp AR, James EC, McNeish I, Dean A, Kim JW, O'Donnell DM, et al. 805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology. 2020;31:S610-S.